home.social

#marstacimab — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #marstacimab, aggregated by home.social.

  1. Hympavzi (marstacimab): New Treatment for Hemophilia
    On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
    #bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
    SCIEU Team

    scientificeuropean.co.uk/medic

  2. Hympavzi (marstacimab): New Treatment for Hemophilia
    On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
    #bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
    SCIEU Team

    scientificeuropean.co.uk/medic

  3. Hympavzi (marstacimab): New Treatment for Hemophilia
    On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
    #bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
    SCIEU Team

    scientificeuropean.co.uk/medic

  4. Hympavzi (marstacimab): New Treatment for Hemophilia
    On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
    #bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
    SCIEU Team

    scientificeuropean.co.uk/medic

  5. Hympavzi (marstacimab): New Treatment for Hemophilia
    On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
    #bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
    SCIEU Team

    scientificeuropean.co.uk/medic